These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 24212944)

  • 1. Dual targeting of the insulin-like growth factor and collateral pathways in cancer: combating drug resistance.
    Ludwig JA; Lamhamedi-Cherradi SE; Lee HY; Naing A; Benjamin R
    Cancers (Basel); 2011 Jul; 3(3):3029-54. PubMed ID: 24212944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IGF-1R and mTOR Blockade: Novel Resistance Mechanisms and Synergistic Drug Combinations for Ewing Sarcoma.
    Lamhamedi-Cherradi SE; Menegaz BA; Ramamoorthy V; Vishwamitra D; Wang Y; Maywald RL; Buford AS; Fokt I; Skora S; Wang J; Naing A; Lazar AJ; Rohren EM; Daw NC; Subbiah V; Benjamin RS; Ratan R; Priebe W; Mikos AG; Amin HM; Ludwig JA
    J Natl Cancer Inst; 2016 Dec; 108(12):. PubMed ID: 27576731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insulin receptor (IR) and insulin-like growth factor receptor 1 (IGF-1R) signaling systems: novel treatment strategies for cancer.
    Singh P; Alex JM; Bast F
    Med Oncol; 2014 Jan; 31(1):805. PubMed ID: 24338270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Crosstalk between epidermal growth factor receptor- and insulin-like growth factor-1 receptor signaling: implications for cancer therapy.
    van der Veeken J; Oliveira S; Schiffelers RM; Storm G; van Bergen En Henegouwen PM; Roovers RC
    Curr Cancer Drug Targets; 2009 Sep; 9(6):748-60. PubMed ID: 19754359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma.
    Desbois-Mouthon C; Baron A; Blivet-Van Eggelpoël MJ; Fartoux L; Venot C; Bladt F; Housset C; Rosmorduc O
    Clin Cancer Res; 2009 Sep; 15(17):5445-56. PubMed ID: 19706799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevated insulin-like growth factor 1 receptor signaling induces antiestrogen resistance through the MAPK/ERK and PI3K/Akt signaling routes.
    Zhang Y; Moerkens M; Ramaiahgari S; de Bont H; Price L; Meerman J; van de Water B
    Breast Cancer Res; 2011 May; 13(3):R52. PubMed ID: 21595894
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the insulin-like growth factor receptor pathway in lung cancer: problems and pitfalls.
    Fidler MJ; Shersher DD; Borgia JA; Bonomi P
    Ther Adv Med Oncol; 2012 Mar; 4(2):51-60. PubMed ID: 22423264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insulin-like growth factor signaling as a therapeutic target in pancreatic cancer.
    Rieder S; Michalski CW; Friess H; Kleeff J
    Anticancer Agents Med Chem; 2011 Jun; 11(5):427-33. PubMed ID: 21492074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resistance pathways relevant to insulin-like growth factor-1 receptor-targeted therapy.
    Hendrickson AW; Haluska P
    Curr Opin Investig Drugs; 2009 Oct; 10(10):1032-40. PubMed ID: 19777391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The expression and significance of insulin-like growth factor-1 receptor and its pathway on breast cancer stem/progenitors.
    Chang WW; Lin RJ; Yu J; Chang WY; Fu CH; Lai A; Yu JC; Yu AL
    Breast Cancer Res; 2013 May; 15(3):R39. PubMed ID: 23663564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IGF system targeted therapy: Therapeutic opportunities for ovarian cancer.
    Liefers-Visser JAL; Meijering RAM; Reyners AKL; van der Zee AGJ; de Jong S
    Cancer Treat Rev; 2017 Nov; 60():90-99. PubMed ID: 28934637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting IGF-1 signaling pathways in gynecologic malignancies.
    Bruchim I; Werner H
    Expert Opin Ther Targets; 2013 Mar; 17(3):307-20. PubMed ID: 23294364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in targeting insulin-like growth factor signaling pathway in cancer treatment.
    You L; Liu C; Tang H; Liao Y; Fu S
    Curr Pharm Des; 2014; 20(17):2899-911. PubMed ID: 23944362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergy between an IGF-1R antibody and Raf/MEK/ERK and PI3K/Akt/mTOR pathway inhibitors in suppressing IGF-1R-mediated growth in hematopoietic cells.
    Bertrand FE; Steelman LS; Chappell WH; Abrams SL; Shelton JG; White ER; Ludwig DL; McCubrey JA
    Leukemia; 2006 Jul; 20(7):1254-60. PubMed ID: 16642049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insulin-like growth factor 1 receptor mediated tyrosine 845 phosphorylation of epidermal growth factor receptor in the presence of monoclonal antibody cetuximab.
    Iyer G; Price J; Bourgeois S; Armstrong E; Huang S; Harari PM
    BMC Cancer; 2016 Oct; 16(1):773. PubMed ID: 27716204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. β-Arrestin-biased agonism as the central mechanism of action for insulin-like growth factor 1 receptor-targeting antibodies in Ewing's sarcoma.
    Zheng H; Shen H; Oprea I; Worrall C; Stefanescu R; Girnita A; Girnita L
    Proc Natl Acad Sci U S A; 2012 Dec; 109(50):20620-5. PubMed ID: 23188799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IGF-1R Inhibition Activates a YES/SFK Bypass Resistance Pathway: Rational Basis for Co-Targeting IGF-1R and Yes/SFK Kinase in Rhabdomyosarcoma.
    Wan X; Yeung C; Heske C; Mendoza A; Helman LJ
    Neoplasia; 2015 Apr; 17(4):358-66. PubMed ID: 25925378
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of forced expression of mutated K-RAS gene on gastrointestinal cancer cell lines and the IGF-1R targeting therapy.
    Matsunaga Y; Adachi Y; Sasaki Y; Koide H; Motoya M; Nosho K; Takagi H; Yamamoto H; Sasaki S; Arimura Y; Tokino T; Carbone DP; Imai K; Shinomura Y
    Mol Carcinog; 2017 Feb; 56(2):515-526. PubMed ID: 27312358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aberrant expression and activation of insulin-like growth factor-1 receptor (IGF-1R) are mediated by an induction of IGF-1R promoter activity and stabilization of IGF-1R mRNA and contributes to growth factor independence and increased survival of the pancreatic cancer cell line MIA PaCa-2.
    Nair PN; De Armond DT; Adamo ML; Strodel WE; Freeman JW
    Oncogene; 2001 Dec; 20(57):8203-14. PubMed ID: 11781836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the insulin-like growth factor receptor and Src signaling network for the treatment of non-small cell lung cancer.
    Min HY; Yun HJ; Lee JS; Lee HJ; Cho J; Jang HJ; Park SH; Liu D; Oh SH; Lee JJ; Wistuba II; Lee HY
    Mol Cancer; 2015 Jun; 14():113. PubMed ID: 26041671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.